- call +1-201-465-4211
- email sales@marketquest.biz
- Call +1-201-465-4211
- Email: sales@marketquest.biz
Building on the huge success of monoclonal antibody therapeutics, the next generation of antibody-based products such as Antibody Drug Conjugate (ADC) and Bispecific Antibody (BsAb) is now opening up new opportunities.
According to our latest study, the global Next Generation Antibody Therapeutics market size was valued at USD 9878.9 million in 2022 and is forecast to a readjusted size of USD 36620 million by 2029 with a CAGR of 20.6% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Global key players of next generation antibody therapeutics include Roche, Seagen, Amgen, Pfizer, Takeda, etc. The top two players hold a share over 70%. North America is the largest market, has a share about 65%, followed by Europe and Asia-Pacific, with share 16% and 15%, separately. In terms of product type, Antibody Drug Conjugate (ADC) is the largest segment, occupied for a share of 60%, and in terms of application, Cancer has a share about 66 percent.
This report is a detailed and comprehensive analysis for global Next Generation Antibody Therapeutics market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Next Generation Antibody Therapeutics market size and forecasts, in consumption value ($ Million), 2018-2029
Global Next Generation Antibody Therapeutics market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Next Generation Antibody Therapeutics market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Next Generation Antibody Therapeutics market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Next Generation Antibody Therapeutics
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Next Generation Antibody Therapeutics market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Amgen, Pfizer, Takeda and Daiichi Sankyo, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market segmentation
Next Generation Antibody Therapeutics market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Antibody Drug Conjugate (ADC)
Bispecific Antibody (BsAb)
Market segment by Application
Cancer
Haemophilia
Other Non-Cancer Diseases
Market segment by players, this report covers
Roche
Amgen
Pfizer
Takeda
Daiichi Sankyo
Seagen
Astellas
Immunomedics
GSK
Immunocore
ADC Therapeutics
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Next Generation Antibody Therapeutics product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Next Generation Antibody Therapeutics, with revenue, gross margin and global market share of Next Generation Antibody Therapeutics from 2018 to 2023.
Chapter 3, the Next Generation Antibody Therapeutics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Next Generation Antibody Therapeutics market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Next Generation Antibody Therapeutics.
Chapter 13, to describe Next Generation Antibody Therapeutics research findings and conclusion.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1.1 Product Overview and Scope of Next Generation Antibody Therapeutics
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Next Generation Antibody Therapeutics by Type
1.3.1 Overview: Global Next Generation Antibody Therapeutics Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Next Generation Antibody Therapeutics Consumption Value Market Share by Type in 2022
1.3.3 Antibody Drug Conjugate (ADC)
1.3.4 Bispecific Antibody (BsAb)
1.4 Global Next Generation Antibody Therapeutics Market by Application
1.4.1 Overview: Global Next Generation Antibody Therapeutics Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Cancer
1.4.3 Haemophilia
1.4.4 Other Non-Cancer Diseases
1.5 Global Next Generation Antibody Therapeutics Market Size & Forecast
1.6 Global Next Generation Antibody Therapeutics Market Size and Forecast by Region
1.6.1 Global Next Generation Antibody Therapeutics Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Next Generation Antibody Therapeutics Market Size by Region, (2018-2029)
1.6.3 North America Next Generation Antibody Therapeutics Market Size and Prospect (2018-2029)
1.6.4 Europe Next Generation Antibody Therapeutics Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Next Generation Antibody Therapeutics Market Size and Prospect (2018-2029)
1.6.6 South America Next Generation Antibody Therapeutics Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Next Generation Antibody Therapeutics Market Size and Prospect (2018-2029)
2 Company Profiles
2.1 Roche
2.1.1 Roche Details
2.1.2 Roche Major Business
2.1.3 Roche Next Generation Antibody Therapeutics Product and Solutions
2.1.4 Roche Next Generation Antibody Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Roche Recent Developments and Future Plans
2.2 Amgen
2.2.1 Amgen Details
2.2.2 Amgen Major Business
2.2.3 Amgen Next Generation Antibody Therapeutics Product and Solutions
2.2.4 Amgen Next Generation Antibody Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Amgen Recent Developments and Future Plans
2.3 Pfizer
2.3.1 Pfizer Details
2.3.2 Pfizer Major Business
2.3.3 Pfizer Next Generation Antibody Therapeutics Product and Solutions
2.3.4 Pfizer Next Generation Antibody Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Pfizer Recent Developments and Future Plans
2.4 Takeda
2.4.1 Takeda Details
2.4.2 Takeda Major Business
2.4.3 Takeda Next Generation Antibody Therapeutics Product and Solutions
2.4.4 Takeda Next Generation Antibody Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Takeda Recent Developments and Future Plans
2.5 Daiichi Sankyo
2.5.1 Daiichi Sankyo Details
2.5.2 Daiichi Sankyo Major Business
2.5.3 Daiichi Sankyo Next Generation Antibody Therapeutics Product and Solutions
2.5.4 Daiichi Sankyo Next Generation Antibody Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Daiichi Sankyo Recent Developments and Future Plans
2.6 Seagen
2.6.1 Seagen Details
2.6.2 Seagen Major Business
2.6.3 Seagen Next Generation Antibody Therapeutics Product and Solutions
2.6.4 Seagen Next Generation Antibody Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Seagen Recent Developments and Future Plans
2.7 Astellas
2.7.1 Astellas Details
2.7.2 Astellas Major Business
2.7.3 Astellas Next Generation Antibody Therapeutics Product and Solutions
2.7.4 Astellas Next Generation Antibody Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Astellas Recent Developments and Future Plans
2.8 Immunomedics
2.8.1 Immunomedics Details
2.8.2 Immunomedics Major Business
2.8.3 Immunomedics Next Generation Antibody Therapeutics Product and Solutions
2.8.4 Immunomedics Next Generation Antibody Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Immunomedics Recent Developments and Future Plans
2.9 GSK
2.9.1 GSK Details
2.9.2 GSK Major Business
2.9.3 GSK Next Generation Antibody Therapeutics Product and Solutions
2.9.4 GSK Next Generation Antibody Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 GSK Recent Developments and Future Plans
2.10 Immunocore
2.10.1 Immunocore Details
2.10.2 Immunocore Major Business
2.10.3 Immunocore Next Generation Antibody Therapeutics Product and Solutions
2.10.4 Immunocore Next Generation Antibody Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Immunocore Recent Developments and Future Plans
2.11 ADC Therapeutics
2.11.1 ADC Therapeutics Details
2.11.2 ADC Therapeutics Major Business
2.11.3 ADC Therapeutics Next Generation Antibody Therapeutics Product and Solutions
2.11.4 ADC Therapeutics Next Generation Antibody Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 ADC Therapeutics Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Next Generation Antibody Therapeutics Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Next Generation Antibody Therapeutics by Company Revenue
3.2.2 Top 3 Next Generation Antibody Therapeutics Players Market Share in 2022
3.2.3 Top 6 Next Generation Antibody Therapeutics Players Market Share in 2022
3.3 Next Generation Antibody Therapeutics Market: Overall Company Footprint Analysis
3.3.1 Next Generation Antibody Therapeutics Market: Region Footprint
3.3.2 Next Generation Antibody Therapeutics Market: Company Product Type Footprint
3.3.3 Next Generation Antibody Therapeutics Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Type
4.1 Global Next Generation Antibody Therapeutics Consumption Value and Market Share by Type (2018-2023)
4.2 Global Next Generation Antibody Therapeutics Market Forecast by Type (2024-2029)
5 Market Size Segment by Application
5.1 Global Next Generation Antibody Therapeutics Consumption Value Market Share by Application (2018-2023)
5.2 Global Next Generation Antibody Therapeutics Market Forecast by Application (2024-2029)
6 North America
6.1 North America Next Generation Antibody Therapeutics Consumption Value by Type (2018-2029)
6.2 North America Next Generation Antibody Therapeutics Consumption Value by Application (2018-2029)
6.3 North America Next Generation Antibody Therapeutics Market Size by Country
6.3.1 North America Next Generation Antibody Therapeutics Consumption Value by Country (2018-2029)
6.3.2 United States Next Generation Antibody Therapeutics Market Size and Forecast (2018-2029)
6.3.3 Canada Next Generation Antibody Therapeutics Market Size and Forecast (2018-2029)
6.3.4 Mexico Next Generation Antibody Therapeutics Market Size and Forecast (2018-2029)
7 Europe
7.1 Europe Next Generation Antibody Therapeutics Consumption Value by Type (2018-2029)
7.2 Europe Next Generation Antibody Therapeutics Consumption Value by Application (2018-2029)
7.3 Europe Next Generation Antibody Therapeutics Market Size by Country
7.3.1 Europe Next Generation Antibody Therapeutics Consumption Value by Country (2018-2029)
7.3.2 Germany Next Generation Antibody Therapeutics Market Size and Forecast (2018-2029)
7.3.3 France Next Generation Antibody Therapeutics Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Next Generation Antibody Therapeutics Market Size and Forecast (2018-2029)
7.3.5 Russia Next Generation Antibody Therapeutics Market Size and Forecast (2018-2029)
7.3.6 Italy Next Generation Antibody Therapeutics Market Size and Forecast (2018-2029)
8 Asia-Pacific
8.1 Asia-Pacific Next Generation Antibody Therapeutics Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Next Generation Antibody Therapeutics Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Region
8.3.1 Asia-Pacific Next Generation Antibody Therapeutics Consumption Value by Region (2018-2029)
8.3.2 China Next Generation Antibody Therapeutics Market Size and Forecast (2018-2029)
8.3.3 Japan Next Generation Antibody Therapeutics Market Size and Forecast (2018-2029)
8.3.4 South Korea Next Generation Antibody Therapeutics Market Size and Forecast (2018-2029)
8.3.5 India Next Generation Antibody Therapeutics Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Next Generation Antibody Therapeutics Market Size and Forecast (2018-2029)
8.3.7 Australia Next Generation Antibody Therapeutics Market Size and Forecast (2018-2029)
9 South America
9.1 South America Next Generation Antibody Therapeutics Consumption Value by Type (2018-2029)
9.2 South America Next Generation Antibody Therapeutics Consumption Value by Application (2018-2029)
9.3 South America Next Generation Antibody Therapeutics Market Size by Country
9.3.1 South America Next Generation Antibody Therapeutics Consumption Value by Country (2018-2029)
9.3.2 Brazil Next Generation Antibody Therapeutics Market Size and Forecast (2018-2029)
9.3.3 Argentina Next Generation Antibody Therapeutics Market Size and Forecast (2018-2029)
10 Middle East & Africa
10.1 Middle East & Africa Next Generation Antibody Therapeutics Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Next Generation Antibody Therapeutics Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Country
10.3.1 Middle East & Africa Next Generation Antibody Therapeutics Consumption Value by Country (2018-2029)
10.3.2 Turkey Next Generation Antibody Therapeutics Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Next Generation Antibody Therapeutics Market Size and Forecast (2018-2029)
10.3.4 UAE Next Generation Antibody Therapeutics Market Size and Forecast (2018-2029)
11 Market Dynamics
11.1 Next Generation Antibody Therapeutics Market Drivers
11.2 Next Generation Antibody Therapeutics Market Restraints
11.3 Next Generation Antibody Therapeutics Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
11.5 Influence of COVID-19 and Russia-Ukraine War
11.5.1 Influence of COVID-19
11.5.2 Influence of Russia-Ukraine War
12 Industry Chain Analysis
12.1 Next Generation Antibody Therapeutics Industry Chain
12.2 Next Generation Antibody Therapeutics Upstream Analysis
12.3 Next Generation Antibody Therapeutics Midstream Analysis
12.4 Next Generation Antibody Therapeutics Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
List of Tables
Table 1. Global Next Generation Antibody Therapeutics Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Next Generation Antibody Therapeutics Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global Next Generation Antibody Therapeutics Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Next Generation Antibody Therapeutics Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Roche Company Information, Head Office, and Major Competitors
Table 6. Roche Major Business
Table 7. Roche Next Generation Antibody Therapeutics Product and Solutions
Table 8. Roche Next Generation Antibody Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Roche Recent Developments and Future Plans
Table 10. Amgen Company Information, Head Office, and Major Competitors
Table 11. Amgen Major Business
Table 12. Amgen Next Generation Antibody Therapeutics Product and Solutions
Table 13. Amgen Next Generation Antibody Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. Amgen Recent Developments and Future Plans
Table 15. Pfizer Company Information, Head Office, and Major Competitors
Table 16. Pfizer Major Business
Table 17. Pfizer Next Generation Antibody Therapeutics Product and Solutions
Table 18. Pfizer Next Generation Antibody Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. Pfizer Recent Developments and Future Plans
Table 20. Takeda Company Information, Head Office, and Major Competitors
Table 21. Takeda Major Business
Table 22. Takeda Next Generation Antibody Therapeutics Product and Solutions
Table 23. Takeda Next Generation Antibody Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. Takeda Recent Developments and Future Plans
Table 25. Daiichi Sankyo Company Information, Head Office, and Major Competitors
Table 26. Daiichi Sankyo Major Business
Table 27. Daiichi Sankyo Next Generation Antibody Therapeutics Product and Solutions
Table 28. Daiichi Sankyo Next Generation Antibody Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. Daiichi Sankyo Recent Developments and Future Plans
Table 30. Seagen Company Information, Head Office, and Major Competitors
Table 31. Seagen Major Business
Table 32. Seagen Next Generation Antibody Therapeutics Product and Solutions
Table 33. Seagen Next Generation Antibody Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. Seagen Recent Developments and Future Plans
Table 35. Astellas Company Information, Head Office, and Major Competitors
Table 36. Astellas Major Business
Table 37. Astellas Next Generation Antibody Therapeutics Product and Solutions
Table 38. Astellas Next Generation Antibody Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. Astellas Recent Developments and Future Plans
Table 40. Immunomedics Company Information, Head Office, and Major Competitors
Table 41. Immunomedics Major Business
Table 42. Immunomedics Next Generation Antibody Therapeutics Product and Solutions
Table 43. Immunomedics Next Generation Antibody Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. Immunomedics Recent Developments and Future Plans
Table 45. GSK Company Information, Head Office, and Major Competitors
Table 46. GSK Major Business
Table 47. GSK Next Generation Antibody Therapeutics Product and Solutions
Table 48. GSK Next Generation Antibody Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 49. GSK Recent Developments and Future Plans
Table 50. Immunocore Company Information, Head Office, and Major Competitors
Table 51. Immunocore Major Business
Table 52. Immunocore Next Generation Antibody Therapeutics Product and Solutions
Table 53. Immunocore Next Generation Antibody Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 54. Immunocore Recent Developments and Future Plans
Table 55. ADC Therapeutics Company Information, Head Office, and Major Competitors
Table 56. ADC Therapeutics Major Business
Table 57. ADC Therapeutics Next Generation Antibody Therapeutics Product and Solutions
Table 58. ADC Therapeutics Next Generation Antibody Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 59. ADC Therapeutics Recent Developments and Future Plans
Table 60. Global Next Generation Antibody Therapeutics Revenue (USD Million) by Players (2018-2023)
Table 61. Global Next Generation Antibody Therapeutics Revenue Share by Players (2018-2023)
Table 62. Breakdown of Next Generation Antibody Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3)
Table 63. Market Position of Players in Next Generation Antibody Therapeutics, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 64. Head Office of Key Next Generation Antibody Therapeutics Players
Table 65. Next Generation Antibody Therapeutics Market: Company Product Type Footprint
Table 66. Next Generation Antibody Therapeutics Market: Company Product Application Footprint
Table 67. Next Generation Antibody Therapeutics New Market Entrants and Barriers to Market Entry
Table 68. Next Generation Antibody Therapeutics Mergers, Acquisition, Agreements, and Collaborations
Table 69. Global Next Generation Antibody Therapeutics Consumption Value (USD Million) by Type (2018-2023)
Table 70. Global Next Generation Antibody Therapeutics Consumption Value Share by Type (2018-2023)
Table 71. Global Next Generation Antibody Therapeutics Consumption Value Forecast by Type (2024-2029)
Table 72. Global Next Generation Antibody Therapeutics Consumption Value by Application (2018-2023)
Table 73. Global Next Generation Antibody Therapeutics Consumption Value Forecast by Application (2024-2029)
Table 74. North America Next Generation Antibody Therapeutics Consumption Value by Type (2018-2023) & (USD Million)
Table 75. North America Next Generation Antibody Therapeutics Consumption Value by Type (2024-2029) & (USD Million)
Table 76. North America Next Generation Antibody Therapeutics Consumption Value by Application (2018-2023) & (USD Million)
Table 77. North America Next Generation Antibody Therapeutics Consumption Value by Application (2024-2029) & (USD Million)
Table 78. North America Next Generation Antibody Therapeutics Consumption Value by Country (2018-2023) & (USD Million)
Table 79. North America Next Generation Antibody Therapeutics Consumption Value by Country (2024-2029) & (USD Million)
Table 80. Europe Next Generation Antibody Therapeutics Consumption Value by Type (2018-2023) & (USD Million)
Table 81. Europe Next Generation Antibody Therapeutics Consumption Value by Type (2024-2029) & (USD Million)
Table 82. Europe Next Generation Antibody Therapeutics Consumption Value by Application (2018-2023) & (USD Million)
Table 83. Europe Next Generation Antibody Therapeutics Consumption Value by Application (2024-2029) & (USD Million)
Table 84. Europe Next Generation Antibody Therapeutics Consumption Value by Country (2018-2023) & (USD Million)
Table 85. Europe Next Generation Antibody Therapeutics Consumption Value by Country (2024-2029) & (USD Million)
Table 86. Asia-Pacific Next Generation Antibody Therapeutics Consumption Value by Type (2018-2023) & (USD Million)
Table 87. Asia-Pacific Next Generation Antibody Therapeutics Consumption Value by Type (2024-2029) & (USD Million)
Table 88. Asia-Pacific Next Generation Antibody Therapeutics Consumption Value by Application (2018-2023) & (USD Million)
Table 89. Asia-Pacific Next Generation Antibody Therapeutics Consumption Value by Application (2024-2029) & (USD Million)
Table 90. Asia-Pacific Next Generation Antibody Therapeutics Consumption Value by Region (2018-2023) & (USD Million)
Table 91. Asia-Pacific Next Generation Antibody Therapeutics Consumption Value by Region (2024-2029) & (USD Million)
Table 92. South America Next Generation Antibody Therapeutics Consumption Value by Type (2018-2023) & (USD Million)
Table 93. South America Next Generation Antibody Therapeutics Consumption Value by Type (2024-2029) & (USD Million)
Table 94. South America Next Generation Antibody Therapeutics Consumption Value by Application (2018-2023) & (USD Million)
Table 95. South America Next Generation Antibody Therapeutics Consumption Value by Application (2024-2029) & (USD Million)
Table 96. South America Next Generation Antibody Therapeutics Consumption Value by Country (2018-2023) & (USD Million)
Table 97. South America Next Generation Antibody Therapeutics Consumption Value by Country (2024-2029) & (USD Million)
Table 98. Middle East & Africa Next Generation Antibody Therapeutics Consumption Value by Type (2018-2023) & (USD Million)
Table 99. Middle East & Africa Next Generation Antibody Therapeutics Consumption Value by Type (2024-2029) & (USD Million)
Table 100. Middle East & Africa Next Generation Antibody Therapeutics Consumption Value by Application (2018-2023) & (USD Million)
Table 101. Middle East & Africa Next Generation Antibody Therapeutics Consumption Value by Application (2024-2029) & (USD Million)
Table 102. Middle East & Africa Next Generation Antibody Therapeutics Consumption Value by Country (2018-2023) & (USD Million)
Table 103. Middle East & Africa Next Generation Antibody Therapeutics Consumption Value by Country (2024-2029) & (USD Million)
Table 104. Next Generation Antibody Therapeutics Raw Material
Table 105. Key Suppliers of Next Generation Antibody Therapeutics Raw Materials
List of Figures
Figure 1. Next Generation Antibody Therapeutics Picture
Figure 2. Global Next Generation Antibody Therapeutics Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Next Generation Antibody Therapeutics Consumption Value Market Share by Type in 2022
Figure 4. Antibody Drug Conjugate (ADC)
Figure 5. Bispecific Antibody (BsAb)
Figure 6. Global Next Generation Antibody Therapeutics Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 7. Next Generation Antibody Therapeutics Consumption Value Market Share by Application in 2022
Figure 8. Cancer Picture
Figure 9. Haemophilia Picture
Figure 10. Other Non-Cancer Diseases Picture
Figure 11. Global Next Generation Antibody Therapeutics Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 12. Global Next Generation Antibody Therapeutics Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 13. Global Market Next Generation Antibody Therapeutics Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 14. Global Next Generation Antibody Therapeutics Consumption Value Market Share by Region (2018-2029)
Figure 15. Global Next Generation Antibody Therapeutics Consumption Value Market Share by Region in 2022
Figure 16. North America Next Generation Antibody Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 17. Europe Next Generation Antibody Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 18. Asia-Pacific Next Generation Antibody Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 19. South America Next Generation Antibody Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 20. Middle East and Africa Next Generation Antibody Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 21. Global Next Generation Antibody Therapeutics Revenue Share by Players in 2022
Figure 22. Next Generation Antibody Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 23. Global Top 3 Players Next Generation Antibody Therapeutics Market Share in 2022
Figure 24. Global Top 6 Players Next Generation Antibody Therapeutics Market Share in 2022
Figure 25. Global Next Generation Antibody Therapeutics Consumption Value Share by Type (2018-2023)
Figure 26. Global Next Generation Antibody Therapeutics Market Share Forecast by Type (2024-2029)
Figure 27. Global Next Generation Antibody Therapeutics Consumption Value Share by Application (2018-2023)
Figure 28. Global Next Generation Antibody Therapeutics Market Share Forecast by Application (2024-2029)
Figure 29. North America Next Generation Antibody Therapeutics Consumption Value Market Share by Type (2018-2029)
Figure 30. North America Next Generation Antibody Therapeutics Consumption Value Market Share by Application (2018-2029)
Figure 31. North America Next Generation Antibody Therapeutics Consumption Value Market Share by Country (2018-2029)
Figure 32. United States Next Generation Antibody Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 33. Canada Next Generation Antibody Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 34. Mexico Next Generation Antibody Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 35. Europe Next Generation Antibody Therapeutics Consumption Value Market Share by Type (2018-2029)
Figure 36. Europe Next Generation Antibody Therapeutics Consumption Value Market Share by Application (2018-2029)
Figure 37. Europe Next Generation Antibody Therapeutics Consumption Value Market Share by Country (2018-2029)
Figure 38. Germany Next Generation Antibody Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 39. France Next Generation Antibody Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 40. United Kingdom Next Generation Antibody Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 41. Russia Next Generation Antibody Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 42. Italy Next Generation Antibody Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 43. Asia-Pacific Next Generation Antibody Therapeutics Consumption Value Market Share by Type (2018-2029)
Figure 44. Asia-Pacific Next Generation Antibody Therapeutics Consumption Value Market Share by Application (2018-2029)
Figure 45. Asia-Pacific Next Generation Antibody Therapeutics Consumption Value Market Share by Region (2018-2029)
Figure 46. China Next Generation Antibody Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 47. Japan Next Generation Antibody Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 48. South Korea Next Generation Antibody Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 49. India Next Generation Antibody Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 50. Southeast Asia Next Generation Antibody Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 51. Australia Next Generation Antibody Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 52. South America Next Generation Antibody Therapeutics Consumption Value Market Share by Type (2018-2029)
Figure 53. South America Next Generation Antibody Therapeutics Consumption Value Market Share by Application (2018-2029)
Figure 54. South America Next Generation Antibody Therapeutics Consumption Value Market Share by Country (2018-2029)
Figure 55. Brazil Next Generation Antibody Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 56. Argentina Next Generation Antibody Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 57. Middle East and Africa Next Generation Antibody Therapeutics Consumption Value Market Share by Type (2018-2029)
Figure 58. Middle East and Africa Next Generation Antibody Therapeutics Consumption Value Market Share by Application (2018-2029)
Figure 59. Middle East and Africa Next Generation Antibody Therapeutics Consumption Value Market Share by Country (2018-2029)
Figure 60. Turkey Next Generation Antibody Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 61. Saudi Arabia Next Generation Antibody Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 62. UAE Next Generation Antibody Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 63. Next Generation Antibody Therapeutics Market Drivers
Figure 64. Next Generation Antibody Therapeutics Market Restraints
Figure 65. Next Generation Antibody Therapeutics Market Trends
Figure 66. Porters Five Forces Analysis
Figure 67. Manufacturing Cost Structure Analysis of Next Generation Antibody Therapeutics in 2022
Figure 68. Manufacturing Process Analysis of Next Generation Antibody Therapeutics
Figure 69. Next Generation Antibody Therapeutics Industrial Chain
Figure 70. Methodology
Figure 71. Research Process and Data Source
Please feel free to write an email to us or to use our electronic ticketing system.
